Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

Describe medications used to manage diabetes and determining goals for therapy.
Determine the utility of electronic glucose management systems in management of diabetic ketoacidosis.
Explain newly approved treatments in metabolic bone disease

Suggested Addtitional Reading:

AACE Algorithm for comprehensive management of diabetes https://www.aace.com/publications/algorithm

https://www.fda.gov/Drugs/DrugSafety/ucm617360.htm

Burosumab Therapy in Children with X-Linked Hypophosphatemia . T. Carpenter et. al. N Engl J Med 2018; 378:1987-1998

Authors:

Jagdeesh Ullal, MD, MS, FACE, FACP, ECNU, CCD — Clinical Associate Professor of Medicine Clinic Lead for Inpatient and Subspecialty Diabetes Division of Endocrinology, Diabetes, and Metabolism University of Pittsburgh
No relationships with industry relevant to the content of this educational activity have been disclosed.

Authors disclosure of relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients is listed above. No other planners, members of the planning committee, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.

The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Pittsburgh School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits^™. Each physician should only claim credit commensurate with the extent of their participation in the activity.

The University of Pittsburgh is an affirmative action, equal opportunity institution.